Drug Trial Radar · NCT07641426
A Two Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection (ABMR).
Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
58
Planned (sponsor's estimate)
Start
Jun 9, 2026
Primary completion
May 2030
Study completion Dec 2030
Sponsor
- Lead sponsor
- CASI pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- CASI Pharmaceuticals (China) Co., Ltd.
- First posted
- Jun 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of the global Phase 1/2 clinical trial is to evaluate whether CID-103, a novel anti-CD38 monoclonal antibody, is safe and effective in adults with with active and chronic active renal allograft antibody mediated rejection (ABMR). The main questions the study aims to answer are:• To evaluate the safety and tolerability of CID-103 in subjects with ABMR with different increasing doses of CID-103.• To evaluate clinical efficacy of CID-103 at an optimal dose in participants with active and chronic active ABMR following renal allograft transplant. The study will be done in two parts: Part A will test increasing doses of CID-103 to see how safe it is and how well people tolerate it. Researchers will also aim to find a safe dose range. Part B will enroll approximately 40 participants to see how well the medicine works and gather more safety and efficacy information. The goal is to find the optimal dose to use in future studies.CID-103 is given through an intravenous (IV) infusion. During the study, participants may receive treatment for up to 12 months, followed by a post-treatment safety follow-up period to check for ongoing safety and effectiveness. This study is an important step toward developing a new treatment for people living with ABMR. If CID-103 is found to be safe and effective, it could offer a new option for patients who do not respond well to current therapies.
Conditions
- Antibody Mediated Rejection
Interventions
CID-103Drug
Following an initial priming dose of 150 mg on Week 1, participants will receive CID-103 at the higher target dose administered for up to a maximum treatment duration of 49 weeks, in the absence of treatment failure or stopping criteria.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Arms A: Number of participants experiencing study-specific safety events or meeting treatment stopping criteriaTime frame: Up to Week 65
- Arms A: Number of participants with AEs with focus on infections, cytopenias, and IRRsTime frame: Up to Week 65
- Arms A: Number of Participants With Serious Adverse Events (SAEs)Time frame: Up to Week 65
- Arms A: Number of Participants With Anti-Drug Antibody (ADA)Time frame: Up to week 65
- Part B: Number of Participants With Achievement of Biopsy-Proven Histologic Resolution of AMR Activity at Week 24Time frame: at Week 24
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Beijing Friendship Hospital
Beijing, Beijing Municipality, China · Active not recruiting
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China · Active not recruiting
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
The First Affiliated Hospital of Medical College of Xi'an Jiaotong University
Xi'an, Shaanxi, China · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.